Fuji to market SmartLight units in Japan
Haifa, Israel-based SmartLight announced this month that Fuji Medical Systems will be the exclusive distributor for the company's digital film viewer systems, computer-controlled light boxes that adjust for glare and ambient light when film is mounted
Haifa, Israel-based SmartLight announced this month that Fuji Medical Systems will be the exclusive distributor for the company's digital film viewer systems, computer-controlled light boxes that adjust for glare and ambient light when film is mounted for viewing. The deal represents a major victory for SmartLight, giving the company access to Fuji's strong distribution channels in the lucrative Japanese market.
SmartLight began shipping the systems in February 1997, and has placed more than 200 systems throughout the world. The SmartLight line comprises the SL2000, which has two 14x17-inch viewing fields, the SL4000, with four fields, and the SL8000 and 8000DLX, which use motorized film-transport technology (SCAN 1/21/98).
Price for the viewers ranges from $25,000 to $85,000, substantially more than conventional light boxes, but the company argues that the systems pay for themselves by eliminating the need for two x-ray study retakes per day (SCAN 5/14/97).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
